奈达铂联合替吉奥同步放疗治疗进展期食管癌的效果分析

Effect of Nedaplatin Combined with Tegio Synchronized Radiotherapy for Advanced Esophageal Cancer

目的:研究奈达铂联合替吉奥同步放疗治疗进展期食管癌的效果。方法:选取2017年4月-2018年4月到笔者所在医院治疗的142例进展期食管癌患者,经数字盲选方式,分为A组(n=71,常规放疗治疗)和B组(n=71,奈达铂联合替吉奥同步放疗治疗),比较两组临床疗效及肿瘤坏死因子-α(TNF-α)、C反应蛋白(CRP)水平。结果:B组临床治疗总有效率为94.37%,高于A组的81.69%,治疗后B组TNF-α、CRP水平均低于A组,差异均有统计学意义(P<0.05)。结论:在进展期食管癌患者中,应用奈达铂联合替吉奥放疗治疗方法,临床效果显著,患者TNF-α、CRP明显改善,值得临床推广。

Objective: To study the effect of Nedaplatin combined with Tegio synchronous radiotherapy in the treatment of advanced esophageal cancer. Method: A total of 142 patients with advanced esophageal cancer who were treated in our hospital from April 2017 to April 2018 were selected as experimental subjects and divided into the group A(n=71, routine treatment) and the group B(n=71, Nedaplatin Combined with Tegio synchronous radiotherapy). The clinical efficacy, tumor necrosis factor-α(TNF-α) and C-reactive protein(CRP) in the two groups were compared. Result: The total effective rate of clinical treatment in group B was 94.37%, which was higher than 81.69% in group A, and the levels of TNF-α and CRP in group B were lower than those in group A after treatment, the differences were statistically significant(P<0.05). Conclusion: In patients with advanced esophageal cancer, the clinical effect of Nedaplatin combined with Tegio synchronous radiotherapy is remarkable. The patients’ TNF-αand CRP are significantly improved, which is worthy of clinical promotion.